D-0831-2020 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0831-2020 was initiated by Teva Pharmaceuticals USA on Jan 27, 2020 and is designated Class II. Reason for recall: GMP Deviations: Product bottle may be absent of desiccant. The recall status is terminated (terminated Dec 10, 2020). Affected quantity: 69,012 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 12, 2020
Initiation Date
Jan 27, 2020
Termination Date
Dec 10, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
69,012 bottles

Product description

Desmopressin Acetate Tablets, 0.2 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2465-01

Reason for recall

GMP Deviations: Product bottle may be absent of desiccant.

Distribution pattern

Nationwide within the United States

Code information

Lot #: 1269726M, exp. date 01/2020; 1283269M, 1283270M, exp. date 03/2020; 1292992M,1292993A, exp. date 04/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0831-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0831-2020. Report a data issue: hello@regdatalab.com.